Discontinuing Blood Thinner Therapy After Successful Atrial Fibrillation Treatment May Reduce Risks
New research indicates that stopping anticoagulation therapy after successful atrial fibrillation ablation may lower risks of stroke and bleeding, offering potential changes to long-term treatment strategies.
Recent research suggests that stopping oral anticoagulation (OAC) medication after a successful atrial fibrillation (AF) ablation procedure could lower the risk of adverse events such as stroke, systemic embolism, and major bleeding. A large trial presented at ESC Congress 2025 and published in the Journal of the American Medical Association examined patients who had undergone their first catheter-based AF ablation at least 12 months prior. These patients had no recurrence of arrhythmia and possessed at least one stroke risk factor based on the CHA2DS2-VASc score.
The trial involved 840 participants randomized equally into two groups: one continuing standard-dose OAC therapy, primarily with apixaban, rivaroxaban, or edoxaban, and the other stopping anticoagulation altogether. Over 24 months, the group that discontinued OAC experienced fewer net adverse clinical events—only 0.3% compared to 2.2% in the continuing therapy group. Interestingly, there was no significant difference in the rates of ischemic stroke or systemic embolism between the groups, with incidences of less than 1% in both.
However, major bleeding was more common in the OAC group, affecting 1.4% of patients, while the no-OAC group had no major bleeding events. Although the study's primary goal was to evaluate overall adverse events, the findings imply that lifelong anticoagulation may not be necessary for all patients after successful AF ablation, especially those without recurrent arrhythmia.
Professor Boyoung Joung from Yonsei University, Seoul, emphasized that this trial is the first to provide randomized evidence that stopping OAC can be safer in select patients, challenging the current guideline recommendations for indefinite anticoagulation based solely on stroke risk factors. Nonetheless, as the trial was not specifically powered to detect differences in ischemic events, further research is needed.
Overall, these findings may influence future guidelines and patient management strategies, potentially reducing the long-term use of blood-thinning medications in patients who have achieved rhythm control after AF ablation. Patients should consult their healthcare providers to individualize treatment decisions based on their specific risk profiles.
Source: MedicalXpress
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Enhancing Pediatric Dental Health: Widespread Adoption of Fluoride Varnish Through Quality Improvement Initiatives
A comprehensive quality improvement initiative significantly increased the application of fluoride varnish in pediatric primary care, promising better oral health outcomes for children nationwide.
Rising Cardiovascular Disease Risk in Mexico Despite Better Cholesterol Management
Despite improved cholesterol control, cardiovascular disease risk has increased in Mexico from 2016 to 2023, highlighting the need for region-specific risk assessment and public health strategies.
Q&A: How Research on Mpox is Preparing Scientists for Future Pandemics
Research on mpox has led to crucial insights into the virus, treatment efficacy, and the role of clinical trials during outbreaks, helping scientists better prepare for future pandemics.
Tragic Death of Boy in South Carolina Linked to Brain-Eating Amoeba
A 12-year-old boy from South Carolina tragically died after contracting Naegleria fowleri, a deadly brain-eating amoeba found in freshwater bodies during summer. The case highlights the importance of water safety and awareness of this rare but fatal infection.